Last checked at 
LONDON (Alliance News) - Scancell Holdings PLC Friday said it has completed patient dosing with 8mg of SCIB1 ImmunoBody in part one of its on-going phase 1/2 clinical trial in patients with Stage III/IV melanoma.
The trial followed a study the firm conducted which showed that a 4mg dose of SCIB1 produced an immune response that might be associated with clinical benefit in patients with malignant melanoma, regulatory approval was granted for a higher dose of 8mg.
Scancell Holdings said five patients with metastatic tumour present were recruited and dosed, with no reported drug or device-related serious adverse events.
"Immunology and clinical responses in this higher dose cohort of patients are currently being analysed and will be reported by the end of second quarter 2014," the firm added.
Regulatory approval to expand part two of the study to include up to 13 patients receiving the 8mg dose was obtained in October last year.
"With the absence of any serious toxicity in the 8mg part one cohort, enrolment into this cohort has now been closed and new patients will be now be recruited into the expanded 8mg part two cohort," Scancell said.
The company said the first such patient was dosed with SCIB1 earlier this week.
The stock was trading at 32.42 pence Friday morning, down 1.42 pence or 4.6%.
By Anthony Tshibangu; anthonytshibangu@alliancenews.com; @AnthonyAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
